SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Cocrystal Pharma, Inc. (COCP) Q3 Net Loss Rises to $3.4M; Phase 1b Dosing Complete

Cocrystal's Q3 2026 net loss was $3.4M versus $2.0M a year earlier; revenue and grant income was $105K versus none. Dosing is complete in its 32-person Phase 1b CDI-988 norovirus challenge study, with preliminary efficacy results expected in late 2026.Material DetailsContext by AI AnalystThis is an…

COCP

Related stories